There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keryx Biopharma (NASDAQ:KERX), G1 Therapeutics Inc (NASDAQ:GTHX) and Sarepta Therapeutics (NASDAQ:SRPT) with bullish sentiments.
Keryx Biopharma (KERX)
H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Keryx Biopharma today and set a price target of $9. The company’s shares closed yesterday at $3.78, close to its 52-week low of $3.30.
Kolbert noted:
“Our therapeutic models are patient-based and reflect our assumptions for the market size and share penetration rates and pricing. We use this to determine the future revenue streams. These metrics then flow into our valuation model.”
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -4.2% and a 39.0% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Can-Fite BioPharma.
Currently, the analyst consensus on Keryx Biopharma is a Moderate Buy with an average price target of $7.33.
See today’s analyst top recommended stocks >>
G1 Therapeutics Inc (GTHX)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics Inc, with a price target of $61. The company’s shares closed yesterday at $51.52, close to its 52-week high of $55.71.
White observed:
“We base our $61 price target on probability-adjusted revenue forecasts for trilaciclib in first-line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 35% POS for both products, a 3x price/sales multiple, and a $2.70/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48, which if approved will compete with Faslodex, a drug that recorded sales of $941M in 2017.”
According to TipRanks.com, White is a 5-star analyst with an average return of 25.7% and a 55.7% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
G1 Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $60.33.
Sarepta Therapeutics (SRPT)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics today and set a price target of $267. The company’s shares closed yesterday at $121.02.
Chattopadhyay commented:
“Our $267 price target is derived from a risk-adjusted (over its entire clinical-stage pipeline) DCF analysis and is based on: beta of 1.80, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.9%, and tax rate of 15% beginning in FY 2024 (Exhibit 4).”
According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -0.2% and a 43.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $198.60, representing a 64.1% upside. In a report issued on August 1, Morgan Stanley also upgraded the stock to Buy with a $163 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRPT:
